Aurobindo Pharma Q4FY26 Revenue Rises 5.6% to ₹8,853 Cr

Aurobindo Pharma reported Q4FY26 revenue of ₹8,853 crore, a 5.6% YoY growth, driven by a 30.2% surge in Europe formulations.
EBITDA was stable at ₹1,801 crore with a 20.3% margin, while PAT grew 2.0% YoY to ₹921 crore.
The company advanced its biosimilars pipeline with Phase 3 completions for Omalizumab and Denosumab, targeting filings in 2026.
Net cash position stood strong at ~$317 million post the acquisition of Khandelwal Labs.